

In vivo and in vitro random mutagenesis techniques in plants

GMO Unit



Background



- In the judgment in Case C-528/16 the Court of Justice of the European Union (CJEU) interpreted the Article 3 of Directive 2001/18 on the deliberate release of Genetically Modified Organisms (OGM) referring to the "application of conventional methods of random mutagenesis" without distinguishing further between *in vivo* and *in vitro* random mutagenesis
- The Conseil d'Etat of France issued on 7 February 2020 a judgment on organisms obtained by mutagenesis, distinguishing between *in vivo* and *in vitro* random mutagenesis techniques
- The EC asked EFSA to clarify whether the distinction between in vitro and in vivo is scientifically justified

Layout



Protocol development

Draft Opinion

> Timeline

Protocol development



Random mutagenesis mandate selected as a pilot


- 'Draft framework for protocol development for EFSA's scientific assessments' (EFSA, 2020)
 - Protocol applied to EFSA's non-application scientific assessments

Protocol development



- Step 1. Problem formulation
 - Translation of ToRs into assessment questions

- Step 2. Definition of methods for addressing the problem
 - Literature search: review papers and book chapters



Protocol development - Literature search



Assistance from the AMU Unit

- Literature search outcome:
 - **517** documents
- Screening of the literature:
 - 2 independent reviewers screened the documents by title and abstract
 - 294 documents retained
 - 75 publications cited in the DO

Draft Opinion - Terms of Reference



- ✓ToR1: To provide a more detailed description of random mutagenesis techniques as applied in vivo and in vitro.
- ✓ToR2: To assess whether the types of genetic modification induced by random mutagenesis techniques are different depending on whether the technique is applied in vivo or in vitro.
- ✓ToR3: To assess whether the molecular mechanism underlying random mutagenesis techniques is different if the techniques are applied in vivo or in vitro.
- ✓ToR4: To assess whether in vitro random mutagenesis techniques are to be considered as different techniques compared to in vivo random mutagenesis techniques or on the contrary, if they are to be considered as a continuum.

Draft Opinion - Assessment



- Introduction
 - Spontaneous and induced mutations in the context of plant breeding
 - Historical view of random mutagenesis in mutation breeding
- Addressing ToR1
 - Q1: What random mutagenesis techniques are used to obtain mutant plants?
 - Mutation breeding: summary of the main steps
 - General considerations of in vivo and in vitro random mutagenesis techniques in plants
 - Physical mutagenesis techniques applied in mutation breeding
 - Chemical mutagenesis techniques applied in mutation breeding
 - Example of in vivo and in vitro mutagenesis applications in plants
 - Q2: Are all these techniques applied both in vivo and in vitro?
 - Sub-conclusion

Draft Opinion - Assessment



Addressing ToR3

- Q1: What are the underlying molecular mechanisms which generate the mutations?
 - Mechanisms leading to DNA damage
 - Mechanisms leading to repair
- Q2: Is there any difference between these molecular mechanisms whether they happen in vivo or in vitro?
 - Sub-conclusion

Addressing ToR2

- Q1: What type of alterations at the DNA level are induced by random mutagenesis?
 - Types of mutations
- Q2: Is there any difference between the mutations whether they are obtained in vivo or in vitro?
 - Sub-conclusion

Draft Opinion - Assessment



Addressing ToR4

- Q: Are *in vitro* and *in vivo* random mutagenesis techniques considered to be different or not?
 - General conclusion based on the assessment

Conclusions

- different physical and chemical mutagenesis techniques have been applied to both in vivo and in vitro
- the process and the repair mechanisms that are triggered by the mutagen act at the cellular level and thus there is no difference in the way the mutagen will affect the DNA whether the mutagen is applied *in vivo* or *in vitro*;
- the type of mutations induced by a specific mutagen are expected to be the same, regardless of whether such mutagen is applied in vivo or in vitro.
- The distinction between plants obtained by *in vitro* or *in vivo* approaches is, therefore, not justified. Indeed, the same mutation can be potentially obtained using both *in vivo* and *in vitro* random mutagenesis and the resulting mutants would be indistinguishable.

Timeline



29/30 **September December** 2021 20-January 5 May <u>Plenary</u> May 21 2021 **Adoption** 2020 Endorseme Literature Receipt search nt for PC

November 2020

Presentation of protocol development

February 2021 – May 2021


Drafting SO

19 May – 30 June 2021

PC

Public Consultation





30/06/2021

Please, submit your comments!

Deadline 30-06-2021

Thanks!



- MC subWG
 - Nils Rostoks (Chair)
 - Josep Casacuberta
 - Philippe Guerche
 - Tamas Dalmay
- MC WG
- MC Team
- GMO panel members
- Irene Pilar Munoz Guajardo, Laura Martino (AMU Unit)

Stay connected





Subscribe to

efsa.europa.eu/en/news/newsletters efsa.europa.eu/en/rss



Receive job alerts

careers.efsa.europa.eu – job alerts



Follow us on Twitter

@efsa_eu

@plants_efsa

@methods_efsa

@animals_efsa



Follow us Linked in

Linkedin.com/company/efsa



Contact us

efsa.europa.eu/en/contact/askefsa